O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
-12.53%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$9.47B
AUM Growth
+$9.47B
(-14%)
Cap. Flow
+$164M
Cap. Flow
% of AUM
1.74%
Top 10 Holdings %
Top 10 Hldgs %
41.65%
Holding
145
New
14
Increased
43
Reduced
27
Closed
6
Top Buys
| 1 |
Vertex Pharmaceuticals
VRTX
|
$95.1M |
| 2 |
Corvus Pharmaceuticals
CRVS
|
$76.2M |
| 3 |
UnitedHealth
UNH
|
$74M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$72.1M |
| 5 |
Eli Lilly
LLY
|
$66.8M |
Top Sells
| 1 |
HNT
HEALTH NET INC
HNT
|
$205M |
| 2 |
Viatris
VTRS
|
$143M |
| 3 |
AFFX
AFFYMETRIX INC
AFFX
|
$75.8M |
| 4 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$56.3M |
| 5 |
Bristol-Myers Squibb
BMY
|
$49.2M |
Sector Composition
| 1 | Healthcare | 90.2% |
| 2 | Financials | 0.22% |
| 3 | Technology | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Ironwood Pharmaceuticals
IRWD
$214M
| $126M | 1.33% | 11,550,400 +324,000 | +3% | +$3.54M |
|
27
Cooper Companies
COO
$13.4B
| $123M | 1.29% | 795,900 -119,000 | -13% | -$18.3M |
|
28
Pfizer
PFE
$141B
| $122M | 1.29% | 4,122,000 -2,000 | -0% | -$59.3K |
|
29
Neurocrine Biosciences
NBIX
$13.8B
| $105M | 1.1% | 2,653,874 +138,900 | +6% | +$5.49M |
|
|
30
UnitedHealth
UNH
$281B
| $105M | 1.1% | 812,000 +574,000 | +241% | +$74M |
|
|
RLYP
31
DELISTED
RELYPSA INC COM
RLYP
| $100M | 1.06% | 7,400,000 | – | – |
|
|
AGN.PRA
32
DELISTED
Allergan plc.
AGN.PRA
| $95.8M | 1.01% | 104,200 | – | – |
|
|
ACHN
33
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $88.9M | 0.94% | 11,519,700 +1,869,800 | +19% | +$14.4M |
|
|
ISEE
34
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $88.5M | 0.93% | 2,094,500 +83,000 | +4% | +$3.51M |
|
|
35
BioMarin Pharmaceuticals
BMRN
$11.2B
| $84.4M | 0.89% | 1,023,200 +874,200 | +587% | +$72.1M |
|
|
TSRO
36
DELISTED
TESARO, Inc.
TSRO
| $84.2M | 0.89% | 1,912,000 +147,300 | +8% | +$6.49M |
|
37
Puma Biotechnology
PBYI
$254M
| $80.9M | 0.85% | 2,753,425 +514,600 | +23% | +$15.1M |
|
|
MNK
38
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $80.2M | 0.84% | 1,309,000 +47,000 | +4% | +$2.88M |
|
|
39
Corvus Pharmaceuticals
CRVS
$428M
| $76.2M | 0.8% | +5,258,450 | New | +$76.2M |
|
|
INSY
40
DELISTED
Insys Therapeutics, Inc.
INSY
| $72.9M | 0.77% | 4,557,740 +191,000 | +4% | +$3.05M |
|
|
NUVA
41
DELISTED
NuVasive, Inc.
NUVA
| $72.3M | 0.76% | 1,487,000 | – | – |
|
42
Humana
HUM
$36.5B
| $62.1M | 0.65% | +339,700 | New | +$62.1M |
|
|
LOXO
43
DELISTED
Loxo Oncology, Inc
LOXO
| $59.5M | 0.63% | 2,175,857 | – | – |
|
44
Johnson & Johnson
JNJ
$427B
| $57.5M | 0.61% | 531,800 +239,800 | +82% | +$25.9M |
|
|
IMGN
45
DELISTED
Immunogen Inc
IMGN
| $51.9M | 0.55% | 6,095,647 | – | – |
|
|
SHPG
46
DELISTED
Shire pic
SHPG
| $51.6M | 0.54% | 300,371 +49,400 | +20% | +$8.49M |
|
47
SPDR S&P Biotech ETF
XBI
$5.07B
| $50.7M | 0.53% | +981,200 | New | +$50.7M |
|
48
Medtronic
MDT
$119B
| $50M | 0.53% | 666,299 +78,000 | +13% | +$5.85M |
|
49
Glaukos
GKOS
$5.5B
| $48.9M | 0.51% | 2,897,938 +1 | +0% | +$17 |
|
50
Cigna
CI
$80.3B
| $46M | 0.48% | 335,500 +53,500 | +19% | +$7.34M |
|